<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01215474</url>
  </required_header>
  <id_info>
    <org_study_id>AZ-NSCLC 18+</org_study_id>
    <nct_id>NCT01215474</nct_id>
  </id_info>
  <brief_title>Pathomolecular Analysis of Rare EGFR Mutations in Advanced NSCLC</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Provitro GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Provitro GmbH</source>
  <brief_summary>
    <textblock>
      While current mutational analyses comprise exons 19 and 21 in which the majority of
      EGFR-mutations occur, this study aims at investigating the relevance of exon 18 and 20
      mutations. Therefore, the investigators analyse 500 routine tumor samples with respect to the
      above mentioned exons and correlate the results to the clinical outcome. This approach will
      enable us to potentially identify patients that might in the future benefit from targeted
      therapy (EGFR-inhibition).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">500</enrollment>
  <condition>Mutations in Exons 18 to 21</condition>
  <arm_group>
    <arm_group_label>NSCLC Stadium III-IV</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who were biopsied and/or received surgery for NSCLC diagnostics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NSCLC Stadium III-IV

        Exclusion Criteria:

          -  no NSCLC or different stadium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Pathology, Charit√© University Medicine Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2010</study_first_submitted>
  <study_first_submitted_qc>October 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2010</study_first_posted>
  <last_update_submitted>June 15, 2011</last_update_submitted>
  <last_update_submitted_qc>June 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2011</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

